Inhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cells

Basit Öğe Kaydı
dc.authoridCanbay, Emel/0000-0001-7592-3000
dc.authoridDedeoglu, Bala Gur/0000-0002-4320-5685
dc.authoridYulug, Isik/0000-0002-7577-2502
dc.authorwosidCanbay, Emel/AAA-8582-2022
dc.authorwosidDedeoglu, Bala Gur/ABC-2436-2020
dc.contributor.authorCanbay, Emel
dc.contributor.authorGur-Dedeoglu, Bala
dc.contributor.authorBozkurt, Betul
dc.contributor.authorKarabeyoglu, Melih
dc.contributor.authorUnal, Bulent
dc.contributor.authorYildirim, Osman
dc.contributor.authorCengiz, Omer
dc.date.accessioned2024-08-04T20:32:18Z
dc.date.available2024-08-04T20:32:18Z
dc.date.issued2008
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPertuzumab (Omnitarg (R), 2C4) is a recombinant humanized monoclonal antibody targeted to extracellular region of HER-2. Previous results proved the inhibitory effect of Pertuzumab on the survival of breast cancer cells via MAPK and AM pathway. Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. Here, we aimed to investigate the effects of Pertuzumab on ligand activated total FAK expression and phosphorylation in the HER-2 overexpressing BT-474 breast cancer cell line. Heregulin,vas used for ligand activation. We have found that FAK expression and phosphorylation were inhibited in with Pertuzumab in breast cancer cells.en_US
dc.description.sponsorshipT.R.State Planing Organization [T-256]en_US
dc.description.sponsorshipWe thank Ms Dina Washington for Pertuzumab (Omnitarg (R), Genentech). This work Was supported by T.R.State Planing Organization Project No: T-256 (E.C.). EC is rotational specialist in Department of General Surgery, Breast Unit, Istanbul University, Istanbul Medical Faculty.en_US
dc.identifier.endpage299en_US
dc.identifier.issn1529-9120
dc.identifier.scopus2-s2.0-77649139830en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage293en_US
dc.identifier.urihttps://hdl.handle.net/11616/94988
dc.identifier.volume12Ben_US
dc.identifier.wosWOS:000265623400015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGene Therapy Pressen_US
dc.relation.ispartofGene Therapy and Molecular Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPertuzumaben_US
dc.subjectOmnitarg (R)en_US
dc.subject2C4en_US
dc.subjectfocal adhesion kinaseen_US
dc.subjectbreast canceren_US
dc.titleInhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu